Rescue of misrouted GnRHR mutants reveals its constitutive activity

Molecular Endocrinology

Volumn 26, Issue 7, 2012, Pages 1179-1188

  Janovick, Jo Ann ^a   Pogozheva, Irina D ^c   Mosberg, Henry I ^c   Cornea, Anda ^a   Michael Conn, P ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GONADORELIN RECEPTOR; INOSITOL PHOSPHATE; MUTANT PROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DNA MODIFICATION; ENDOPLASMIC RETICULUM; GENE DELETION; GENE MUTATION; IC 50; INTRACELLULAR TRANSPORT; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; COS CELLS; ENDOPLASMIC RETICULUM; HUMANS; INOSITOL PHOSPHATES; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN TRANSPORT; RECEPTORS, LHRH;

EID: 84863326309     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2012-1089     Document Type: Article

References (56)

1. Janovick JA, Goulet M, Bush E, Greer J, Wettlaufer DG, Conn PM 2003 Structure-activity relations of successful pharmacologic chap-erones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther 305:608-614
2. Brothers SP, Cornea A, Janovick JA, Conn PM 2004 Human loss-of-function gonadotropin-releasing hormone receptor mutants retain wild-type receptors in the endoplasmic reticulum: molecular basis of the dominant-negative effect. Mol Endocrinol 18:1787-1797
3. Janovick JA, Brothers SP, Cornea A, Bush E, Goulet MT, Ashton WT, Sauer DR, Haviv F, Greer J, Conn PM 2007 Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro. Mol Cell Endocrinol 272:77-85
4. Janovick JA, Patny A, Mosley R, Goulet MT, Altman MD, Rush TS, Cornea A, Conn PM 2009 Molecular mechanism of action of pharmacoperone rescue of misrouted GPCR mutants: the GnRH receptor. Mol Endocrinol 23:157-168
5. Janovick JA, Maya-Nunez G, Conn PM 2002 Rescue of hypogo-nadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87:3255-3262
6. Leaños-Miranda A, Janovick JA, Conn PM 2002 Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonado-tropic hypogonadism. J Clin Endocrinol Metab 87:4825-4828
7. Leaños-Miranda A, Ulloa-Aguirre A, Janovick JA, Conn PM 2005 In vitro coexpression and pharmacological rescue of mutant gonad-otropin-releasing hormone receptors causing hypogonadotropic hypogonadism in humans expressing compound heterozygous alleles. J Clin Endocrinol Metab 90:3001-3008
8. Leaños-Miranda A, Ulloa-Aguirre A, Ji TH, Janovick JA, Conn PM. 2003 Dominant-negative action of disease-causing gonadotropin-releasing hormone receptor (GnRHR) mutants: a trait that potentially coevolved with decreased plasma membrane expression of GnRHR in humans. J Clin Endocrinol Metab 88:3360-3367
9. Conn PM, Knollman PE, Brothers SP, Janovick JA 2006 Protein folding as posttranslational regulation: evolution of a mechanism for controlled plasma membrane expression of a G protein-coupled receptor. Mol Endocrinol 20:3035-3041
10. Janovick JA, Knollman PE, Brothers SP, Ayala-Yáñez R, Aziz AS, Conn PM 2006 Regulation of G protein-coupled receptor trafficking by inefficient plasma membrane expression: molecular basis of an evolved strategy. J Biol Chem 281:8417-8425
11. Knollman PE, Janovick JA, Brothers SP, Conn PM 2005 Parallel regulation of membrane trafficking and dominant-negative effects by misrouted gonadotropin-releasing hormone receptor mutants. J Biol Chem 280:24506-24514
12. Conn PM, Janovick JA 2009 Drug development and the cellular quality control system. Trends Pharmacol Sci 30:228-233
13. Maya-Núñez G, Janovick JA, Aguilar-Rojas A, Jardón-Valadez E, Leaños-Miranda A, Zariñan T, Ulloa-Aguirre A, Conn PM 2011 Biochemical mechanism of pathogenesis of human gonadotropin-releasing hormone receptor mutants Thr104Ile and Tyr108Cys associated with familial hypogonadotropic hypogonadism. Mol Cell Endocrinol 337:16-23
14. Conn PM, Ulloa-Aguirre A 2011 Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors. Adv Pharmacol 62:109-141
15. Tao YX 2008 Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 120:129-148
16. Bond RA, Ijzerman AP 2006 Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 27:92-96
17. Janovick JA, Conn PM 2010 Salt bridge integrates GPCR activation with protein trafficking. Proc Natl Acad Sci USA 107:4454-4458
18. Janovick JA, Park BS, Conn PM 2011 Therapeutic rescue of mis-folded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs. PLoS One 6:e22784
19. Janovick JA, Pogozheva ID, Mosberg HI, Conn PM 2011 Salt bridges overlapping the gonadotropin-releasing hormone receptor agonist binding site reveal a coincidence detector for g protein-coupled receptor activation. J Pharmacol Exp Ther 338:430-442
20. Flanagan CA, Rodic V, Konvicka K, Yuen T, Chi L, Rivier JE, Millar RP, Weinstein H, Sealfon SC 2000 Multiple interactions of the Asp(2.61(98)) side chain of the gonadotropin-releasing hormone receptor contribute differentially to ligand interaction. Biochemistry 39:8133-8141
21. Zhou W, Rodic V, Kitanovic S, Flanagan CA, Chi L, Weinstein H, Maayani S, Millar RP, Sealfon SC 1995 A locus of the gonadotro-pin-releasing hormone receptor that differentiates agonist and antagonist binding sites. J Biol Chem 270:18853-18857
22. Maya-Núñez G, Janovick JA, Ulloa-Aguirre A, Söderlund D, Conn PM, Méndez JP 2002 Molecular basis of hypogonadotropic hypo-gonadism: restoration of mutant (E(90)K) GnRH receptor function by a deletion at a distant site. J Clin Endocrinol Metab 87:2144-2149
23. Janovick JA, Brothers SP, Knollman PE, Conn PM 2007 Specializations of a G-protein-coupled receptor that appear to aid with detection of frequency-modulated signals from its ligand. FASEB J 21:384-392
24. Lin X, Janovick JA, Brothers S, Blömenrohr M, Bogerd J, Conn PM 1998 Addition of catfish gonadotropin-releasing hormone (GnRH) receptor intracellular carboxyl-terminal tail to rat GnRH receptor alters receptor expression and regulation. Mol Endocrinol 12:161-171
25. Lin X, Cornea A, Janovick JA, Conn PM 1998 Visualization of unoccupied and occupied gonadotropin-releasing hormone receptors in living cells. Mol Cell Endocrinol 146:27-37
26. Conn PM, Janovick JA 2009 Trafficking and quality control of the gonadotropin releasing hormone receptor in health and disease. Mol Cell Endocrinol 299:137-145
27. Huckle WR, Conn PM 1987 Use of lithium ion in measurement of stimulated pituitary inositol phospholipid turnover. Methods En-zymol 141:149-155
28. Conn PM, Leaños-Miranda A, Janovick JA 2002 Protein origami: therapeutic rescue of misfolded gene products. Mol Interv 2:308- 316
29. Ulloa-Aguirre A, Janovick JA, Brothers SP, Conn PM 2004 Phar-macologic rescue of conformationally-defective proteins: implications for the treatment of human disease. Traffic 5:821-837
30. Castro-Fernández C, Maya-Núñez G, Conn PM 2005 Beyond the signal sequence: protein routing in health and disease. Endocr Rev 26:479-503
31. Cook JV, Eidne KA 1997 An intramolecular disulfide bond between conserved extracellular cysteines in the gonadotropin-releas-ing hormone receptor is essential for binding and activation. Endocrinology 138:2800-2806
32. Janovick JA, Ulloa-Aguirre A, Conn PM 2003 Evolved regulation of gonadotropin-releasing hormone receptor cell surface expression. Endocrine 22:317-327
33. Ulloa-Aguirre A, Janovick JA, Leaños-Miranda A, Conn PM 2003 Misrouted cell surface receptors as a novel disease aetiology and potential therapeutic target: the case of hypogonadotropic hypogo-nadism due to gonadotropin-releasing hormone resistance. Expert Opin Ther Targets 7:175-185
34. Brothers SP, Janovick JA, Maya-Nunez G, Cornea A, Han XB, Conn PM 2002 Conserved mammalian gonadotropin-releasing hormone receptor carboxyl terminal amino acids regulate ligand binding, effector coupling and internalization. Mol Cell Endocrinol 190:19-27
35. Brothers SP, Janovick JA, Conn PM 2003 Unexpected effects of epitope and chimeric tags on gonadotropin-releasing hormone receptors: implications for understanding the molecular etiology of hypogonadotropic hypogonadism. J Clin Endocrinol Metab 88: 6107-6112
36. Kohout TA, Xie Q, Reijmers S, Finn KJ, Guo Z, Zhu YF, Struthers RS 2007 Trapping of a nonpeptide ligand by the extracellular domains of the gonadotropin-releasing hormone receptor results in insurmountable antagonism. Mol Pharmacol 72:238-247
37. Betz SF, Reinhart GJ, Lio FM, Chen C, Struthers RS 2006 Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor. J Med Chem 49:637-647
38. Davidson JS, Flanagan CA, Zhou W, Becker II, Elario R, Emeran W, Sealfon SC, Millar RP 1995 Identification of N-glycosylation sites in the gonadotropin-releasing hormone receptor: role in receptor expression but not ligand binding. Mol Cell Endocrinol 107: 241-245
39. Davidson JS, McArdle CA, Davies P, Elario R, Flanagan CA, Millar RP 1996 Asn102 of the gonadotropin-releasing hormone receptor is a critical determinant of potency for agonists containing C-ter-minal glycinamide. J Biol Chem 271:15510-15514
40. Standfuss J, Edwards PC, D'Antona A, Fransen M, Xie G, Oprian DD, Schertler GF 2011 The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 471:656-660
41. Salon JA, Lodowski DT, Palczewski K 2011 The significance of G protein-coupled receptor crystallography for drug discovery. Pharmacol Rev 63:901-937
42. Katritch V, Abagyan R 2011 GPCR agonist binding revealed by modeling and crystallography. Trends Pharmacol Sci 32:637-643
43. Lebon G, Warne T, Edwards PC, Bennett K, Langmead CJ, Leslie AG, Tate CG 2011 Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474: 521-525
44. Myburgh DB, Pawson AJ, Davidson JS, Flanagan CA, Millar RP, Hapgood JP 1998 A single amino acid substitution in transmembrane helix VI results in overexpression of the human GnRH receptor. Eur J Endocrinol 139:438-447
45. Costa T, Herz A1989 Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci USA 86:7321-7325
46. White CD 2009 Dissection of GnRH receptor-G protein coupling. In: Medical research council human reproductive sciences unit. Edinburgh: University of Aberdeen; 1-281
47. Han M, Smith SO, Sakmar TP 1998 Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 37:8253-8261
48. Kim JM, Altenbach C, Kono M, Oprian DD, Hubbell WL, Khorana HG 2004 Structural origins of constitutive activation in rhodopsin: role of the K296/E113 salt bridge. Proc Natl Acad Sci USA 101: 12508-12513
49. Proneth B, Xiang Z, Pogozheva ID, Litherland SA, Gorbatyuk OS, Shaw AM, Millard WJ, Mosberg HI, Haskell-Luevano C 2006 Molecular mechanism of the constitutive activation of the L250Q human melanocortin-4 receptor polymorphism. Chem Biol Drug Des 67:215-229
50. Saito H, Kubota M, Roberts RW, Chi Q, Matsunami H 2004 RTP family members induce functional expression of mammalian odor-ant receptors. Cell 119:679-691
51. Pietilä EM, Tuusa JT, Apaja PM, Aatsinki JT, Hakalahti AE, Ra-janiemi HJ, Petäjä-Repo UE 2005 Inefficient maturation of the rat luteinizing hormone receptor. A putative way to regulate receptor numbers at the cell surface. J Biol Chem 280:26622-26629
52. Petrovska R, Kapa I, Klovins J, Schiöth HB, Uhlén S 2005 Addition of a signal peptide sequence to the a1D-adrenoceptor gene increases the density of receptors, as determined by [3H]-prazosin binding in the membranes. Br J Pharmacol 144:651-659
53. Morello JP, BichetDG2001 Nephrogenic diabetes insipidus. Annu Rev Physiol 63:607-630
54. Uberti MA, Hague C, Oller H, Minneman KP, Hall RA 2005 Het-erodimerization with β2-adrenergic receptors promotes surface expression and functional activity of α1D-adrenergic receptors. J Pharmacol Exp Ther 313:16-23
55. Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello JP, Bouvier M 2002 Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J 21:1628-1637
56. Bichet DG 2006 Nephrogenic diabetes insipidus. Adv Chronic Kidney Dis 13:96-104